The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
Open accessAbstract
Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Venn diagrams of genes upregulated in MM cell lines after additional IL-6 stimulation. The MM-STAT3 signature contains 15 upregulated genes shared by studies of Brocke-Heidrich K, et al. (B-H.K., ref. [21]) and Tsuyama N (T.N., ref. [22]).](https://figures.cochat.ai/paper-figures/8edacda888dd49b5bd9c7340f3dca7c6/biological-hallmarks-and-emerging-strategies-to-target-stat3-signaling-in-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the abnormal activation of the JAK/STAT pathway has been identified as a key factor driving the development of MM [107].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [107]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“Janus tyrosine kinases (JAKs)-STAT pathway was originally discovered in the context of interleukin-mediated inflammatory response [15].”
BackgroundKumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,177
Diagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
A Phosphatase Associated with Metastasis of Colorectal Cancer
Saha, S., Bardelli, A., Buckhaults, P., Velculescu, V. E., Rago, C., Croix, B. S., Romans, K. E., Choti, M. A., Lengauer, C., Kinzler, K. W., et al. (2001) · Science · doi:10.1126/science.1065817 · Cited by 648
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Self-citationHyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 4×
“The innate immune system serves as the first line of defense that consists of natural killer (NK) cells, mast cells, eosinophils, basophils, macrophages, neutrophils, dendritic cells (DCs) and humoral factors (cytokines and complement).”
BackgroundInfluentialBroyl, A., Hose, D., Lokhorst, H., de Knegt, Y., Peeters, J., Jauch, A., Bertsch, U., Buijs, A., Stevens-Kroef, M., Beverloo, H. B., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261032 · Cited by 329
Bharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., & Aggarwal, B. B. (2004) · Blood · doi:10.1182/blood-2003-06-2151 · Cited by 318
Signal transduction via integrin adhesion complexes
Humphries, J. D., Chastney, M. R., Askari, J. A., & Humphries, M. J. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.08.004 · Cited by 278
Formation and role of exosomes in cancer
Brinton, L. T., Sloane, H. S., Kester, M., & Kelly, K. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1764-3 · Cited by 244
Wang, J., De Veirman, K., Faict, S., Frassanito, M. A., Ribatti, D., Vacca, A., & Menu, E. (2016) · The Journal of Pathology · doi:10.1002/path.4712 · Cited by 231
Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 200
PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase
Wang, H., Vardy, L. A., Tan, C. P., Loo, J. M., Guo, K., Li, J., Lim, S. G., Zhou, J., Chng, W. J., Ng, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.028 · Cited by 172
Self-citationStructural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains
Wojciak, J. M., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.30 · Cited by 170
Scuto, A., Krejčí, P., Popplewell, L. L., Wu, J., wang, Y., Kujawski, M., Kowolik, C. M., Xin, H., Chen, L., Wang, Y., et al. (2010) · Leukemia · doi:10.1038/leu.2010.289 · Cited by 161
Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., Löffler, D., Koczan, D., Thiesen, H., Burger, R., Gramatzki, M., & Horn, F. (2003) · Blood · doi:10.1182/blood-2003-04-1048 · Cited by 154
Savino, R., Lahm, A., Salvati, A. L., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C., & Ciliberto, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06389.x · Cited by 128
Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Cardona‐Benavides, I. J., Ramón, C. D., & Gutierrez, N. C. (2021) · Cells · doi:10.3390/cells10020336 · Cited by 127
Chatterjee, M., Stühmer, T., Herrmann, P., Bommert, K., Dörken, B., & Bargou, R. C. (2004) · Blood · doi:10.1182/blood-2004-04-1670 · Cited by 124
Ogura, M., Uchida, T., Terui, Y., Hayakawa, F., Kobayashi, Y., Taniwaki, M., Takamatsu, Y., Naoe, T., Tobinai, K., Munakata, W., et al. (2015) · Cancer Science · doi:10.1111/cas.12683 · Cited by 123
Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma
Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017) · Blood · doi:10.1182/blood-2016-10-745059 · Cited by 113
Teoh, P. J., An, Ö., Chung, T., Chooi, J.-Y., Toh, S. H. M., Fan, S., Wang, W., Koh, B. T. H., Fullwood, M. J., Ooi, M. G. M., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832576 · Cited by 110
Self-citationBispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 110
Fagerli, U., Holt, R. U., Holien, T., Våtsveen, T. K., Zhan, F., Egeberg, K. W., Barlogie, B., Waage, A., Aarset, H., Dai, H. Y., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101139 · Cited by 108
Chatterjee, M., Hönemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., Mathas, S., Dörken, B., & Bargou, R. C. (2002) · Blood · doi:10.1182/blood-2002-01-0102 · Cited by 101
Xiong, S., Chng, W. J., & Zhou, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03756-3 · Cited by 101
Self-citationThe Linker Domain of Stat1 Is Required for Gamma Interferon-Driven Transcription
Yang, E., Wen, Z., Haspel, R. L., Zhang, J. J., & Darnell, J. E., Jr. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.5106 · Cited by 99
The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation
Snyder, M., He, W., & Zhang, J. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507479102 · Cited by 95
Ogiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood · doi:10.1182/blood.2019004332 · Cited by 92
Tassone, P., Neri, P. E., Burger, R., Savino, R., Shammas, M. A., Catley, L. P., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2611 · Cited by 91
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma
Chong, P. S. Y., Zhou, J., Lim, J. S. L., Hee, Y. T., Chooi, J.-Y., Chung, T., Tan, Z. T., Zeng, Q., Waller, D. D., Sébag, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0343 · Cited by 85
Self-citationLi, J., Favata, M. F., Kelley, J. A., Caulder, E., Thomas, B. A., Wen, X., Sparks, R. B., Arvanitis, A., Rogers, J. D., Combs, A. P., et al. (2010) · Neoplasia · doi:10.1593/neo.91192 · Cited by 84
Lin, L., Cao, L., Liu, Y., Wang, K., Zhang, X., Qin, X., Zhao, D., Hao, J., Chang, Y., Huang, X., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0331-6 · Cited by 83
Monaghan, K., Khong, T. T., Burns, C. J., & Spencer, A. G. (2011) · Leukemia · doi:10.1038/leu.2011.175 · Cited by 81
Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis, A., Bernassola, F., Savino, R., Melino, G., & Ciliberto, G. (1996) · PubMed · Cited by 66
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Smedt, E. D., Lui, H., Maes, K., Veirman, K. D., Menu, E., Vanderkerken, K., & Bruyne, E. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00566 · Cited by 66
Hönemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dörken, B., & Bargou, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1388 · Cited by 65
Chen, H., Li, M., Sanchez, E., Soof, C. M., Bujarski, S. E., Ng, N., Cao, J., Hekmati, T., Zahab, B., Nosrati, J. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16158 · Cited by 64
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
Meads, M. B., Fang, B., Mathews, L., Gemmer, J. Y., Nong, L., Rosado-Lopez, I., Nguyen, T., Ring, J., Matsui, W. H., MacLeod, A. R., et al. (2015) · Oncogene · doi:10.1038/onc.2015.334 · Cited by 63
Santo, L., Hideshima, T., Cirstea, D., Bandi, M., Nelson, E., Gorgun, G., Rodig, S., Vallet, S., Pozzi, S., Patel, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3012 · Cited by 61
Burger, R., Gouill, S. L., Tai, Y., Shringarpure, R., Tassone, P., Neri, P., Podar, K., Catley, L. P., Hideshima, T., Chauhan, D., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0149 · Cited by 60
IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
Teoh, P. J., Chung, T.-H., Chng, P. Y. Z., Toh, S. H. M., & Chng, W. J. (2020) · Haematologica · doi:10.3324/haematol.2019.221176 · Cited by 60
Self-citationRomano, A., Parrinello, N. L., Simeon, V., Puglisi, F., Cava, P. L., Bellofiore, C., Giallongo, C., Camiolo, G., D’Auria, F., Grieco, V., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58859-x · Cited by 56
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
Hideshima, T., Mitsiades, C. S., Ikeda, H., Chauhan, D., Raje, N. S., Görgün, G., Hideshima, H., Munshi, N. C., Richardson, P. G. G., Carrasco, D. R., et al. (2010) · Blood · doi:10.1182/blood-2010-02-270082 · Cited by 52
Management of multiple myeloma in Asia: resource-stratified guidelines
Tan, D. C. L., Chng, W. J., Chou, T., Nawarawong, W., Hwang, S.-Y., Chim, C. S., Chen, W.-M., Durie, B. G. M., & Lee, J. H. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70404-2 · Cited by 50
Self-citationTassone, P., Galea, E., Forciniti, S., Tagliaferri, P., & Venuta, S. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.4.867 · Cited by 48
The emerging roles of exosomes in leukemogeneis
Zhou, J., Wang, S. C., Sun, K., & Chng, W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9333 · Cited by 43
Self-citationde Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., Fernando, R. C., Sanson, L. F. G., de Carvalho, M. F., Braga, W. M. T., Davies, F. E., & Colleoni, G. W. B. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.016 · Cited by 40
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Perrot, A., Corre, J., & Avet‐Loiseau, H. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200879 · Cited by 40
Genomic heterogeneity in multiple myeloma
Szalat, R. E., & Munshi, N. C. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.03.008 · Cited by 39
Zhou, J., Chan, Z.-L., Bi, C., Lu, X., Chong, P. S. Y., Chooi, J.-Y., Cheong, L.-L., Liu, S.-C., Ching, Y. Q., Zhou, Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0275-t · Cited by 39
Self-citationAwada, H. K., Thapa, B., Awada, H., Dong, J., Gurnari, C., Hari, P., & Dhakal, B. (2021) · Cells · doi:10.3390/cells10081961 · Cited by 39
Berenson, J. R., To, J., Spektor, T. M., Martinez, D., Turner, C., Sánchez, A., Ghermezi, M., Eades, B., Swift, R. A., Schwartz, G. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1899 · Cited by 38
Hosen, N. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00113-y · Cited by 38
LEO1 Is Regulated by PRL-3 and Mediates Its Oncogenic Properties in Acute Myelogenous Leukemia
Chong, P. S. Y., Zhou, J., Cheong, L.-L., Liu, S.-C., Qian, J., Guo, T., Sze, S. K., Zeng, Q., & Chng, W. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2321 · Cited by 33
Self-citationSlørdahl, T. S., Abdollahi, P., Vandsemb, E. N., Rampa, C., Misund, K., Baranowska, K. A., Westhrin, M., Waage, A., Rø, T. B., & Børset, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8422 · Cited by 33
Tsuyama, N., Danjoh, I., Otsuyama, K., Obata, M., Tahara, H., Ohta, T., & Ishikawa, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.036 · Cited by 30
Tassone, P., Forciniti, S., Galea, E., Savino, R., Turco, M. C., Iacopino, P., Tagliaferri, P., Morrone, G., Ciliberto, G., & Venuta, S. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400635 · Cited by 29
Daratumumab for the treatment of multiple myeloma
Goldsmith, S. R., Foley, N. C., & Schroeder, M. A. (2021) · Drugs of today · doi:10.1358/dot.2021.57.10.3313853 · Cited by 29
Chen, H., Li, M., Ng, N., Yu, E., Bujarski, S. E., Yin, Z., Wen, M., Hekmati, T., Field, D., Wang, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17282 · Cited by 28
Zhou, J., Chong, P. S. Y., Lu, X., Cheong, L.-L., Bi, C., Liu, S.-C., Zhou, Y., Tan, T. Z., Yang, H. H., Chung, T., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.08.001 · Cited by 26
Self-citationFüchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 25
A role for IFN-λ1 in multiple myeloma B cell growth
Novak, A. J., Grote, D. M., Ziesmer, S. C., Rajkumar, S. V., Doyle, S. E., & Ansell, S. M. (2008) · Leukemia · doi:10.1038/leu.2008.263 · Cited by 22
Protein tyrosine phosphatases in multiple myeloma
Abdollahi, P., Köhn, M., & Børset, M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.042 · Cited by 22
Jung, S., Lee, Y.-K., Lee, H., Choi, N.-R., Vo, M.-C., Hoang, M.-D., Lim, M.-S., Nguyen-Pham, T.-N., Kim, H., & Lee, J. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.008 · Cited by 19
Petrucci, M. T., Ricciardi, M. R., Ariola, C., Gregorj, C., Ribersani, M., Savino, R., Ciliberto, G., & Tafuri, A. (1999) · Annals of Hematology · doi:10.1007/s002770050465 · Cited by 17
Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors
Tasker, N. R., Rastelli, E. J., Burnett, J. C., Sharlow, E. R., Lazo, J. S., & Wipf, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.048 · Cited by 15
Zhang, Z., Wang, W., Ma, D., Xiong, J., Kuang, X., Zhang, S., Fang, Q., & Wang, J. (2020) · Aging · doi:10.18632/aging.102996 · Cited by 13
Lee, H., McCulloch, S., Mahé, E., Shafey, M., Rashid-Kolvear, F., Khan, F. M., Prajapati, D., Neri, P. E., Duggan, P. R., Tay, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16533 · Cited by 6
Cited by
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Guan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33
Alimohammadi, M., Rahimzadeh, P., Khorrami, R., Bonyadi, M., Daneshi, S., Nabavi, N., Raesi, R., Farani, M. R., Dehkhoda, F., Taheriazam, A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155401 · Cited by 29
Zhang, C., Zhao, Y., Wang, Q., Qin, J., Ye, B., Xu, C., & Yu, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158661 · Cited by 16
Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions
Cleanclay, W. D., Zakari, S., Adigun, T. O., Ayeni, T. O., Nnaji, P. C., Amuji, D. N., Blessing, A., Adebosoye, A., Gbadebo, M., Agbetuyi-Tayo, P., et al. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i12.4 · Cited by 21
Metadata
- Authors
- Zhou, J., & Chng, W.-J.
- Affiliations
- National University of Singapore (SG)
- Corresponding author
- Zhou, Jianbiao
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 11
- Issue
- 6
- Pages
- 941
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8946161
- OpenAlex
- W4220897706
- Semantic Scholar
- 35302bba7072be204b2a89ad7b2ecd88623ab85c
- Cited by
- 22
- References
- 74
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 1
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- National University of Singapore
- National Research Foundation Singapore
- National Medical Research Council (CIRG19nov-0006)
- Institute for Health Innovation and Technology, National University of Singapore
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- multiple myeloma, STAT3 signaling, cancer hallmarks, tumor microenvironment, immunosuppression, JAK inhibitors, STAT3 inhibitor, clinical trials, plasma cells
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Signal Transduction, STAT3 Transcription Factor, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.